Leerink views Lilly and Sarepta as defensive stocks in turbulent market

Crispr Therapeutics AG

06/08/2024 13:36

** Brokerages Leerink Partners says Eli Lilly  LLY.N  and
Sarepta Therapeutics  SRPT.O  are among stocks it expects to
outperform the broader market in "this turbulent period" of
recession concerns
    ** Brokerage expects strong performance from the weight-loss
and diabetes drug maker LLY on Wed, when it reports its earnings
    ** SRPT is a "a potential haven for investors seeking
downside protection in a choppy market" due to potential of
blockbuster sales from its Duchenne gene therapy Elevidys -
Leerink
    ** Brokerage also expects AstraZeneca  AZN.L , McKesson
 MCK.N , Cencora  COR.N  and Thermo Fisher Scientific  TMO.N  to
outperform
    ** Merck  MRK.N , Vaxcyte  PCVX.O  and Bruker  BRKR.O  are
among cos that are "worth revisiting now" as the current
sell-off is a near-term opportunity to buy these stocks which
had faced pressure recently due to difficult newsflow or share
performance - Leerink
    ** BMO Capital Markets says SRPT, besides CRISPR
Therapeutics  CRSP.BN , Biomarin  BMRN.O  and Legend Biotech
 LEGN.O  are among companies that are "undervalued" for their
strong product revenue which could provide protection for sharp
decline
    ** Global stock markets saw a decline in the last session as
weak economic data raised worries of a U.S. recession

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; https://twitter.com/LeroyLeo7;))